Edesa Biotech Inc (EDSA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Edesa Biotech Inc (EDSA) has a cash flow conversion efficiency ratio of -0.142x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.77 Million) by net assets ($12.45 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Edesa Biotech Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Edesa Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read EDSA current and long-term liabilities for a breakdown of total debt and financial obligations.
Edesa Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Edesa Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Unibap AB
ST:UNIBAP
|
-0.136x |
|
Electricite et Eaux de Madagascar SA
PA:EEM
|
-0.200x |
|
Winfarm
PA:ALWF
|
0.152x |
|
Touchwood Entertainment Limited
NSE:TOUCHWOOD
|
-0.092x |
|
Dataworks Group Ltd
AU:DWG
|
-32.658x |
|
Umpas Holding AS
IS:UMPAS
|
-0.256x |
|
Muza S.A
WAR:MZA
|
0.019x |
|
GEN Restaurant Group, Inc. Class A Common Stock
NASDAQ:GENK
|
-0.015x |
Annual Cash Flow Conversion Efficiency for Edesa Biotech Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Edesa Biotech Inc from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see EDSA market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $12.32 Million | $-7.32 Million | -0.594x | +75.92% |
| 2024-09-30 | $1.98 Million | $-4.89 Million | -2.468x | -162.17% |
| 2023-09-30 | $7.05 Million | $-6.64 Million | -0.942x | +27.99% |
| 2022-09-30 | $9.39 Million | $-12.28 Million | -1.308x | -24.95% |
| 2021-09-30 | $13.06 Million | $-13.66 Million | -1.046x | -39.16% |
| 2020-09-30 | $6.63 Million | $-4.99 Million | -0.752x | +18.44% |
| 2019-09-30 | $5.26 Million | $-4.85 Million | -0.922x | -125.45% |
| 2018-09-30 | $11.29 Million | $-4.62 Million | -0.409x | +35.62% |
| 2017-09-30 | $7.40 Million | $-4.70 Million | -0.635x | -73.60% |
| 2016-09-30 | $12.31 Million | $-4.51 Million | -0.366x | +33.62% |
| 2015-09-30 | $8.01 Million | $-4.41 Million | -0.551x | +0.52% |
| 2014-09-30 | $7.70 Million | $-4.27 Million | -0.554x | -159.51% |
| 2013-09-30 | $-3.14 Million | $-2.92 Million | 0.931x | +120.08% |
| 2012-09-30 | $851.61K | $-3.95 Million | -4.636x | -713.47% |
| 2011-09-30 | $4.59 Million | $-2.62 Million | -0.570x | -92.42% |
| 2010-09-30 | $2.47 Million | $-732.23K | -0.296x | -281.29% |
| 2009-09-30 | $484.95K | $-37.67K | -0.078x | -- |
About Edesa Biotech Inc
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-… Read more